Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 4Completed 3Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Plasma cell 2Classical hematology 2Breast 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 98daratumumab 57Lenalidomide 53Bortezomib 38pomalidomide 37Cyclophosphamide 37carfilzomib 25Calcium Dobesilate 25fludarabine 22talquetamab 19iberdomide 18isatuximab 17Specimen Handling 17Magnetic Resonance Spectroscopy 17Biopsy 15selinexor 13dexamethasone acetate 12belantamab mafodotin 12Melphalan 12dexamethasone 21-phosphate 11auricularum 10venetoclax 8fludarabine phosphate 7elotuzumab 7X-Rays 6tocilizumab 5Blood Specimen Collection 5ruxolitinib 4ixazomib 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Tretinoin × Plasma cell × Clear all
NCT06536413 2026-04-03

ATRA

The Methodist Hospital Research Institute

Phase 1/2 Recruiting
42 enrolled
Plasma cell

Multiple Myeloma

NCT06158412 2025-02-19

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting
25 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡